The UK Kidney Association, UK position statement for patients: novel corona virus infection and the use of blood pressure medications

15th March 2020

Recent media reports that ACE Inhibitor drugs (‘pril’ drugs) and Angiotensin receptor blockers (‘sartan’ drugs) may increase the risk of death from novel corona virus (COVID-19) infection will provoke anxiety for many people with kidney disease and leave them uncertain about the best action to take.

Patients are prescribed these medications for a number of reasons and for some people, particularly those with heart failure, stopping the drugs suddenly can lead them to become unwell. This can cause people to become more breathless and may create uncertainty about whether symptoms are due to infection (such as COVID-19), or to underlying health problems.

The evidence that these medications increase the risk of death is unconvincing: the reports may simply reflect the fact that people taking the drugs are more likely to have conditions that place them at high risk of severe COVID-19 infection.

We therefore advise people taking these medications to continue to take them. If they become unwell such that they need to seek medical help, the doctor may advise stopping the drugs depending on their clinical condition.

We are continuing to review the evidence as it comes in and will update this advice as needed.


NICE accredited clinical practice guidelines 

Available here

25th Annual Report

Analyses about the care provided to patients at UK renal centres.

Read the report

2022 UKRR AKI Report

A report on the nationwide collection of AKI warning test scores. 

Read the report